Physician profile
Sheila Silverman
NPI 1326062498
$6,468.48
in general payments reported to CMS, 2019-2025
39 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,487 · 2020: $560 · 2021: $12.30 · 2022: $124 · 2023: $537 · 2024: $1,157 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281 · Education: $4.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.77 |
| Education | $4.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,064.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $767.78 | 2019-2025 | Airsupra, Breztri, Bevespi Aerosphere |
| Janssen Pharmaceuticals, INC | $465.33 | 2019-2023 | Spravato |
| Lilly USA, LLC | $416.79 | 2019-2025 | Mounjaro, Kisunla, Jardiance |
| Amgen INC. | $371.96 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.76 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $320.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.39 | 2019-2020 | |
| Astellas Pharma US INC | $299.32 | 2019-2025 | Veozah |
| Abbott Laboratories | $282.34 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $267.32 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $241.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $182.84 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $140.98 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $99.32 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.